Pinnacle Wealth Management Advisory Group LLC Grows Position in Gilead Sciences, Inc. $GILD

Pinnacle Wealth Management Advisory Group LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,881 shares of the biopharmaceutical company’s stock after acquiring an additional 506 shares during the period. Pinnacle Wealth Management Advisory Group LLC’s holdings in Gilead Sciences were worth $3,867,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after buying an additional 11,156,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Gilead Sciences by 12.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after acquiring an additional 1,520,809 shares in the last quarter. Nuveen LLC bought a new stake in Gilead Sciences during the 1st quarter valued at $620,415,000. Finally, Nordea Investment Management AB increased its holdings in shares of Gilead Sciences by 39.8% in the 2nd quarter. Nordea Investment Management AB now owns 3,956,933 shares of the biopharmaceutical company’s stock valued at $436,648,000 after acquiring an additional 1,126,886 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD opened at $118.84 on Friday. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $124.61. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a market cap of $147.46 billion, a P/E ratio of 23.67, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The firm’s 50-day moving average price is $116.49 and its 200-day moving average price is $112.22.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the business earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Activity

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. The trade was a 1.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer directly owned 157,055 shares in the company, valued at $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 71,500 shares of company stock valued at $8,336,040 over the last ninety days. 0.27% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on GILD shares. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Royal Bank Of Canada boosted their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research note on Friday, October 31st. Finally, TD Cowen increased their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $127.82.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.